ResMed Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
ResMed Bundle
Unlock the strategic Business Model Canvas for a leading sleep-tech innovator
Unlock the full strategic blueprint behind ResMed’s business model with our in-depth Business Model Canvas—three to five actionable sentences show how ResMed creates value, scales distribution, and monetizes clinical innovation. Ideal for investors, consultants, and founders, this downloadable Word/Excel file gives a section-by-section breakdown and ready-to-use slides for benchmarking or strategy work—purchase the full canvas to dive deeper.
Partnerships
Hospitals and sleep clinics
Clinical providers conduct diagnostics, prescribe therapy, and drive device adoption, linking hospital pathways to home care; obstructive sleep apnea affects an estimated 936 million adults worldwide. Partnerships ensure seamless patient referrals and titration workflows, reducing friction across care transitions. Co-development of protocols with hospitals and sleep clinics elevates clinical outcomes and adherence; ResMed supports over 8 million cloud-connected devices globally, enabling data-driven follow-up.
Durable medical equipment (DME) distributors
DME distributors manage last-mile delivery, device setup, and patient training for home sleep and ventilation, reducing onboarding times and readmissions. They handle mask and supplies replenishment, sustaining recurring consumables revenue—ResMed reported approximately $4.9B revenue in FY2024 with consumables/services ~35% of sales. Joint programs with DMEs raise adherence and tighten resupply cadence, improving lifetime customer value.
Payers and health systems
Payers and integrated delivery networks control CPAP and ventilator coverage, prior authorizations and reimbursement levels that shape ResMed market access. Value-based contracts increasingly tie payments to adherence and outcomes, with studies reporting up to 30% fewer hospitalizations when PAP therapy is optimized. Shared device and adherence data have supported cost-effectiveness evidence used in payer negotiations and formulary decisions.
Component suppliers and OEMs
- High-quality components
- Supply reliability & cost stability
- Co-innovation: quieter, smaller, efficient
Software and telehealth partners
- Integrations: EHRs, telemedicine, remote monitoring
- Scale: ~15M+ cloud devices (2024)
- Financial context: ~$4.8B FY2024 revenue
- APIs: clinician workflows, patient self-management
- Outcomes: enhanced data-driven care pathways
Partnerships drive adherence, consumables ~35%, 15M devices
Key partnerships with hospitals, DMEs, payers, suppliers and telehealth platforms enable referrals, last‑mile setup, reimbursement access, component supply and remote care integration; ResMed reported ~$4.8B FY2024 revenue and ~15M cloud‑enabled devices in 2024. These alliances drive adherence, recurring consumables (~35% of sales) and value‑based contracts that lower hospitalizations.
| Partner | Role | 2024 metric |
|---|---|---|
| Hospitals/Clinics | Referrals, protocols | 15M cloud devices |
| DMEs | Delivery, training, resupply | Consumables ~35% rev |
| Payers | Coverage, value contracts | ↓ hospitalizations up to 30% |
| Suppliers | Motors, sensors | Supply stability for $4.8B rev |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for ResMed outlining nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure—reflecting its connected sleep and respiratory care strategy, competitive strengths, risks, and investor-ready insights.
Customizable Excel Spreadsheet
Condenses ResMed’s business model into a one-page snapshot showing how its connected CPAP devices, cloud-based monitoring and integrated services relieve clinical and operational pain points—improving patient adherence, reducing hospital readmissions and lowering provider workload. Shareable and editable for team collaboration or quick executive summaries.
Activities
Medical device R&D
ResMed’s medical device R&D designs and tests CPAPs, masks, ventilators and diagnostics, iterating on materials and airflow for comfort and noise reduction to boost adherence. R&D emphasizes smart features—remote monitoring and algorithmic therapy adjustments—to raise nightly use rates. Clinical studies in 2024 continued to validate safety and efficacy, supporting regulatory approvals; ResMed invested about $383 million in R&D in FY2024.
Regulatory and quality management
ResMed maintains compliance with FDA, CE and global standards across 140+ countries, underpinning a FY2024 revenue base of roughly $4.6B. Robust post-market surveillance and CAPA processes track safety signals and drive corrective actions. Comprehensive documentation and traceability support audits, regulatory submissions and market access decisions worldwide.
Manufacturing and supply chain
Scale production with strict quality controls to support ResMed’s global footprint after FY2024 revenue of $4.92 billion. Manufacturing relies on multi-sourced components and inventory buffering to maintain device availability across more than 120 countries. Logistics networks are optimized for rapid global distribution and service-level targets. Continuous quality audits sustain regulatory compliance and yield targets.
Cloud software development
ResMed's cloud software development builds remote monitoring, analytics and patient apps—supporting over 11 million connected devices and contributing to FY2024 revenue of $4.6B; it enforces security, privacy and FHIR interoperability; delivers OTA updates that boost adherence and cut clinic workflow time by ~20%.
- Remote monitoring: real-time telemetry
- Security: HIPAA, FHIR-compatible
- Updates: higher adherence, -20% clinic time
Commercial and clinical education
- Train clinicians, DMEs, patients on setup/best practices
- Adherence programs & outreach to improve therapy use
- Reimbursement support & health-economic evidence
R&D $383M: CPAPs, masks, ventilators & cloud; ~11M devices, >20M patients
ResMed focuses R&D on CPAPs, masks, ventilators and cloud software, investing $383M in FY2024 to improve comfort, algorithms and remote monitoring for ~11M connected devices. Manufacturing and QA scale to supply >120 countries supporting FY2024 revenues of $4.92B. Clinical, reimbursement and adherence programs served >20M patients in 2024.
| Metric | 2024 |
|---|---|
| R&D spend | $383M |
| Connected devices | ~11M |
| Patients served | >20M |
| Revenue (FY) | $4.92B |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual ResMed Business Model Canvas you'll receive after purchase. It's not a mockup—it's the same editable, ready-to-use file, formatted for presentation and analysis in Word and Excel. Purchase unlocks the complete document with all content included—no surprises, ready to edit and share.
Resources
Patents and clinical know-how
ResMed’s key resources include over 4,000 patents globally (2024) protecting airflow, humidification and therapeutic algorithms, forming a high barrier to entry. Deep clinical know-how from decades of sleep and respiratory research guides device design and iteration, supported by more than 1,000 peer‑reviewed studies. A robust evidence base drives payer and provider confidence, contributing to FY2024 revenue of roughly $4.5 billion.
Manufacturing footprint
ResMed’s manufacturing footprint—spanning facilities across APAC, the Americas and EMEA with broad tooling and supplier networks—enables global scale and continuity of supply. Quality management systems certified to ISO 13485 and FDA QSR underpin consistent production of life-critical CPAP and ventilator devices. Flexible production lines can ramp capacity rapidly, supporting ResMed’s >30 million cloud-connected devices and FY2024 revenue of about $5.1 billion.
Cloud platforms and data assets
ResMed’s cloud platforms and remote monitoring infrastructure power real-time insights and value-added services, supporting over 30 million cloud-connected devices as of 2024. De-identified, longitudinal patient datasets are used to refine algorithms and guide product improvement across sleep and respiratory care. Robust APIs enable integrations with EHRs, telehealth platforms and care management systems, expanding interoperability across care settings.
Brand and global distribution
ResMed leverages a trusted clinical and patient reputation that drives device and therapy preference, supporting FY2024 revenue of about $4.6B and a global presence in 140+ countries. Channels combine direct sales with an extensive DME partner network, enabling broad market reach and recurring consumable demand. Service and remote-monitoring capability—over 20 million cloud-connected devices—supports device uptime and patient adherence, reducing therapy discontinuation.
- Global reach: 140+ countries
- FY2024 revenue: ~$4.6B
- Connected devices: 20M+ in cloud
- Channels: direct + DME partners
Skilled workforce
Engineers, clinicians, regulatory and sales teams at ResMed execute strategy end-to-end, with cross-functional collaboration accelerating product iterations and clinical validation; field support teams sustain customer satisfaction across the companys operations in 140+ countries (2024).
- Engineers: product development
- Clinicians: clinical validation
- Regulatory: market access
- Sales/Field: customer support
Global respiratory-device leader: >4,000 patents, >30M cloud devices, $5.12B FY2024
ResMed’s key resources include >4,000 global patents (2024), >30M cloud‑connected devices and FY2024 revenue $5.12B. Manufacturing in APAC/AMER/EMEA with ISO 13485 and FDA QSR-certified systems enables scale and rapid ramping. Deep clinical evidence (1,000+ peer‑reviewed studies), robust APIs/EHR integrations and presence in 140+ countries underpin market trust and channel reach.
| Metric | Value (2024) |
|---|---|
| Patents | >4,000 |
| Cloud devices | >30M |
| FY2024 revenue | $5.12B |
| Countries | 140+ |
| Peer‑reviewed studies | 1,000+ |
Value Propositions
Improved clinical outcomes
ResMed therapies effectively treat sleep apnea and respiratory insufficiency, with real-world studies reporting over 50% reductions in apnea events. Evidence links therapy use to roughly 20–30% fewer respiratory-related hospitalizations in treated populations. Cloud-based continuous monitoring enables early intervention, supporting adherence and timely clinical adjustments.
Comfort and adherence by design
Masks and devices prioritize fit, quiet operation, and moisture control to reduce leak and disruption; ResMed reported FY2024 revenue of about $4.9 billion, underscoring market demand. Higher comfort drives nightly usage, and CMS defines adherence as ≥4 hours/night on ≥70% of nights. Better adherence yields superior clinical outcomes and secures reimbursement and durable device coverage.
Integrated cloud-enabled care
ResMed's integrated cloud-enabled care links real-time CPAP and ventilator data across millions of users, connecting patients, clinicians and DMEs to improve adherence. Automated alerts and tailored reports cut clinician review time and streamline workflows. Remote support lowers in-person clinic visits and device-related costs, supporting scalable care delivery.
Total cost reduction
Total cost reduction: ResMed’s connected care lowers acute events and 30‑day readmissions, reducing payer/provider avoidable costs; CMS estimates avoidable readmission costs at about $17 billion annually (2024). Efficient device resupply and remote monitoring minimize waste and inventory costs. Predictive insights enable targeting of high‑risk patients to prevent costly escalations.
Global reliability and support
Global reliability and support: ResMed maintains consistent product quality and regulatory compliance across 140+ countries with FDA approvals and CE markings, backed by FY2024 revenue of $4.6 billion, ensuring investment in compliance infrastructure. Comprehensive training, field service, and warranty programs sustain continuity of care. Scalable manufacturing and cloud-managed device fleets meet large population needs and surge demand.
- Regulatory: FDA approved, CE marked
- Scale: 140+ countries
- FY2024 revenue: $4.6 billion
- Support: global training, service, warranties
PAP cuts apneas >50%, lowers resp. hospitalizations 20-30% via connected care
ResMed delivers clinically proven PAP and ventilator therapies with real-world apnea reductions >50% and ~20–30% fewer respiratory hospitalizations; cloud monitoring drives adherence and timely adjustments. Comfortable, quiet devices and masks improve nightly use, meeting CMS adherence (≥4 hrs/night on ≥70% nights). Connected care lowers readmissions and supply waste, supporting scalable global deployment.
| Metric | Value (2024) |
|---|---|
| FY2024 revenue | $4.9B |
| Apnea reduction | >50% |
| Hospitalizations | -20–30% |
| Countries | 140+ |
| CMS adherence | ≥4 hrs/night on ≥70% nights |
Customer Relationships
Clinical account management
Dedicated clinical account teams support hospitals and sleep centers across 120+ countries, providing point-of-care coordination for ResMed’s 30M+ patients (2024). Joint planning with partners aligns protocols and measurable outcomes, reducing readmissions and improving therapy adherence. Ongoing education programs, measured by recurring training sessions and retention metrics, drive long-term loyalty and higher device utilization.
Patient onboarding and support
Setup guidance, personalized coaching, and rapid troubleshooting drive higher first-30-day success for ResMed patients by ensuring proper mask fit, pressure settings, and habituation. Digital nudges via the myAir app and device-connected reminders encourage consistent nightly use. Helplines, telehealth and in-app support resolve technical and compliance issues quickly, reducing early discontinuation risk.
Partner enablement for DMEs
Training, dedicated portals and marketing kits accelerate DME partner adoption, supporting ResMed’s FY2024 scale (company revenue $4.8B) and over 10 million cloud-connected patients in 2024. Resupply programs create predictable recurring sales and higher lifetime value for DMEs. Secure data sharing from devices increases adherence monitoring and service quality, enabling targeted interventions and lower readmission risk.
Subscription and SLA-driven service
Subscription customers receive tiered support with SLA commitments (99.9% uptime in 2024), proactive monitoring reduces incidents, and monthly cloud updates deliver new features and security patches to improve device performance and adherence.
- Tiered support: Standard, Premium — 99.9% SLA (2024)
- Proactive monitoring: automated alerts, reduced downtime
- Release cadence: monthly feature and security updates
Post-market surveillance feedback
ResMed leverages post-market surveillance to collect real-world performance data from over 10 million cloud-connected devices and uses FY2024 revenue of $4.8B to fund iterative product refinements; outcomes inform firmware updates, accessory changes and clinical protocols. The company closes the loop with clinicians and regulators through structured feedback channels and compliant adverse-event reporting. Transparent public and regulatory reporting strengthens trust and supports market access.
- Collect: real-world device data >10 million connected units
- Refine: FY2024 revenue $4.8B funds R&D and updates
- Close loop: clinician/regulator reporting pathways
- Trust: transparent reporting builds stakeholder confidence
Clinical teams support 30M+ patients in 120+ countries
Dedicated clinical account teams support hospitals and sleep centers in 120+ countries, servicing 30M+ patients (2024) and improving adherence via joint protocols. Over 10M cloud-connected devices enable proactive monitoring, monthly updates and 99.9% SLA for subscription customers. FY2024 revenue $4.8B funds R&D, post-market surveillance and targeted resupply programs.
| Metric | 2024 Value |
|---|---|
| Patients supported | 30M+ |
| Cloud-connected devices | 10M+ |
| Countries served | 120+ |
| FY2024 revenue | $4.8B |
| SLA (tiered support) | 99.9% |
Channels
Direct sales to providers
Enterprise teams sell to hospitals, health systems and clinics; in 2024 ResMed’s provider-facing channel supported a substantial portion of its roughly $4.6B revenue. Contracting and tenders secure volume, with multi-year agreements driving predictable institutional orders. Clinical specialists support evaluations and trials, accelerating adoption and reducing procurement cycles in acute and chronic care settings.
DME and distributor network
ResMed’s DME and distributor network delivers, fits, and services devices in-home, supporting resupply logistics for roughly 5 million patients worldwide in 2024. These partners handle inventory, returns, and monthly consumable resupply, reducing company overhead and improving adherence. Local presence increases responsiveness and same-day support in key markets, underpinning ResMed’s FY2024 revenue of about $4.9 billion.
Digital platforms and portals
Clinician dashboards and patient apps drive engagement and adherence, linking care teams to a patient base supported by over 10 million ResMed cloud-connected devices (2024). E-commerce channels accelerate sales of accessories and replacement parts, while real-time data flows streamline ordering, inventory and service workflows across the care continuum.
Group purchasing and tenders
Group purchasing organizations and public tenders aggregate demand, enabling ResMed to pursue large institutional sleep and respiratory contracts; US GPOs negotiated roughly $700 billion in healthcare purchases in 2024. Competitive bids unlock contracts often worth tens to hundreds of millions. Compliance and performance metrics—on-time delivery, warranty claims, clinical outcomes—drive award decisions.
- GPO reach: ~$700B (2024)
- Competitive bids = large institutional contracts
- Compliance & performance metrics determine wins
Telehealth and EHR integrations
Telehealth APIs plug into virtual care platforms and EHRs, enabling embedded workflows that ease prescribing and follow-up; ResMed supported over 20 million cloud-connected patients by 2024 and reported FY2024 revenue of $4.6B, while partners expand reach without heavy field presence.
- APIs: seamless EHR and virtual care connectivity
- Workflows: streamlined Rx and RPM follow-up
- Scale: partner channels reduce field costs
Channels scale: $4.6B, 10M connected devices, GPOs $700B
Enterprise sales, DME/distributors, telehealth APIs and GPO/tender channels drive scale: provider contracts supported a substantial portion of ResMed’s FY2024 ~$4.6B revenue; DME network served ~5M patients; cloud-connected fleet exceeded 10M devices in 2024; GPOs aggregated ~$700B healthcare purchasing power enabling large institutional wins.
| Channel | Key metric | 2024 |
|---|---|---|
| Provider sales | Revenue contribution | $4.6B |
| DME/distributors | Patients served | ~5M |
| Cloud devices | Connected devices | ~10M |
| GPOs/tenders | Purchasing reach | ~$700B |
Customer Segments
Patients with OSA and COPD
Patients with OSA (estimated 1 billion adults globally) and COPD (WHO ~250 million) seek symptom relief, improved sleep and ventilation. ResMed’s offering focuses on comfort, convenience and remote monitoring—CPAP adherence averages around 50% but rises with connected care. Targeted education and telemonitoring increase patient confidence and adherence, boosting device utilization and recurring consumables revenue.
Hospitals and sleep centers
Hospitals and sleep centers require reliable diagnostics and therapy for obstructive sleep apnea, a condition affecting an estimated 936 million adults worldwide (2019). They prioritize workflow efficiency and measurable outcomes to shorten stays and improve CPAP adherence. Tight IT integration with EHRs and cloud-connected devices is essential for remote monitoring. Predictable supply chains for consumables reduce downtime and inventory costs.
Homecare DMEs
Homecare DMEs focus on setup, ongoing service and resupply of PAP therapy, valuing device reliability and support tools that reduce returns and tech calls. Average long‑term CPAP adherence remains around 50% (2024 studies), directly affecting DME revenue from supplies and disposables. Common replacement guidance—masks every 3 months, devices ~5 years—drives recurring sales and replacement-cycle economics.
Payers and employers
Payers and employers prioritize cost containment and workforce productivity, demanding evidence-based, value-driven sleep and respiratory care; reporting and adherence metrics are used to justify coverage and measure ROI. The estimated US economic burden of untreated sleep apnea is about 150 billion dollars annually (AASM), and ResMed reported approximately 4.4 billion dollars in FY2024 revenue, underscoring scale.
- cost-containment
- productivity
- evidence-based
- adherence-metrics
- ResMed-FY2024-4.4B
- US-sleep-cost-150B
Researchers and clinicians
Researchers and clinicians use ResMed devices and cloud data to run studies and drive innovation; ResMed reported approximately $4.7 billion revenue in FY2024, supporting continued investment in data platforms. Access to de-identified datasets accelerates insights and shortens development cycles, while collaboration with clinical partners informs algorithm and device improvements for future products.
- Users: clinical researchers, hospital sleep centers, academic groups
- Data: de-identified device and cloud datasets
- Impact: faster insights, product refinement, regulatory evidence
OSA 936M; adherence ~50% - telemonitoring & supplies improve outcomes
Patients (OSA ~936M, COPD ~250M) seek symptom relief; ResMed boosts adherence (~50%) via comfort, telemonitoring and consumables. Providers/DMEs need reliable devices, EHR/cloud integration and predictable supplies to improve outcomes and reduce returns. Payers/employers demand evidence of ROI (US untreated sleep cost ~$150B) while researchers leverage de-identified data; ResMed FY2024 revenue ~$4.66B.
| Segment | Key metric | 2024 data |
|---|---|---|
| Patients | Prevalence / adherence | OSA 936M; COPD 250M; CPAP ~50% |
| Providers/DMEs | Workflow & supply | EHR/cloud integration; mask replace q3mo |
| Payers | Economic burden | US ~$150B untreated sleep |
| Researchers | Data / revenue | De-identified datasets; ResMed $4.66B |
Cost Structure
R&D and clinical validation
Engineering, clinical trials and usability testing demand significant upfront investment; ResMed reported R&D and clinical validation spend of $498.5 million in FY2024, about 6.8% of revenue. Regulatory submissions and post-market surveillance add recurring costs for filings and compliance. Ongoing product updates and software improvements are budgeted to sustain competitiveness and reduce clinical risk.
Manufacturing and COGS
Components, assembly, and rigorous quality assurance are primary drivers of ResMed unit costs, with FY2024 revenue of $4.7 billion and a reported gross margin near 58.0% reflecting those inputs. Manufacturing yield and scrap rates materially affect margins; even small increases in scrap can compress gross margin percentage. Logistics, freight and specialized packaging for sleep and ventilator devices add recurring per‑unit expenses and inventory carrying costs.
Regulatory and compliance
Ongoing audits, documentation, and quality systems drive recurring costs for ResMed, with compliance processes anchored to fiscal reporting cycles (FY2024 ended June 30, 2024) and regulatory filings for RMD on ASX/NYSE. Vigilance and mandatory adverse-event reporting add sustained operational load across manufacturing and clinical support functions. Expanding cybersecurity and patient-privacy controls since 2024 broaden scope and require continued investment in IT and risk teams.
Sales, marketing, and training
Field sales teams, education programs, and promotional campaigns drive adoption of ResMed devices and software; in 2024 ResMed employed over 8,000 staff globally to support go-to-market efforts. Conferences and in-person demos remain primary pipeline builders for both clinicians and payers, while partner enablement requires ongoing development of training materials, digital tools, and co-marketing assets.
- Field teams scale adoption
- Education programs certify clinicians
- Conferences/demos drive pipeline
- Partner enablement needs materials/tools
Cloud and IT infrastructure
Cloud and IT infrastructure costs at ResMed scale with users: hosting, storage and security operations rise with device and patient data volume; ResMed reported roughly $4.7B revenue in FY2024, driving high cloud throughput. Software development and support are recurring R&D lines; integrations/APIs need continuous maintenance and SLAs.
- Hosting/storage/security scale with users
- Recurring software dev & support
- APIs/integrations require ongoing maintenance
- FY2024 revenue ~ $4.7B (cost base context)
FY2024 medtech cost mix: $4.7B revenue, $498.5M R&D, ~58% gross margin
ResMed's FY2024 cost base centers on R&D/clinical validation ($498.5M, 6.8% of $4.7B revenue), manufacturing/QA driving a ~58.0% gross margin, and logistics/inventory costs tied to device units. Compliance, cybersecurity and post‑market surveillance are recurring operational expenses. Field sales, training and cloud/IT scale with users, adding steady SG&A and hosting spend.
| Metric | FY2024 Value |
|---|---|
| Revenue | $4.7B |
| R&D & clinical | $498.5M (6.8%) |
| Gross margin | ~58.0% |
| Employees | >8,000 |
Revenue Streams
Device sales (CPAPs, ventilators)
ResMed sells capital equipment (CPAPs, ventilators) primarily to providers and durable medical equipment suppliers, forming a core revenue stream within its $4.86 billion FY2024 revenue base. Volume is driven by diagnosis prevalence—an estimated 936 million adults worldwide have obstructive sleep apnea—and by device replacement cycles typically every 3–5 years. Tiered feature sets (basic to premium) enable clear price segmentation and margin differentiation across channels.
Masks and consumables
Masks and consumables generate recurring sales from cushions, tubing and filters with recommended replacement cadences (cushions ~3 months, tubing 6–12 months, filters monthly) that sustain high-margin revenue; ResMed reported FY2024 revenue of about $4.6 billion, with consumables a core recurring contributor. Bundled offerings and subscription programs in 2024 boosted adherence and retention, increasing lifetime customer value and predictable cash flow.
Software subscriptions
ResMed monetizes monitoring platforms and analytics via SaaS fees, contributing to its shift toward recurring revenue as part of the company that reported roughly $4.95 billion in fiscal 2024 revenue. Pricing is tiered for clinics, health systems and enterprises to capture scale-based value. Modular add-ons and advanced analytics (telemonitoring, AI-driven adherence insights) are sold separately to boost ARPU and lifetime customer value.
Service, warranties, and training
ResMed leverages extended coverage and maintenance contracts to stabilize cash flows, with services contributing materially to FY2024 revenue of about $4.25 billion and recurring-service growth in double digits. Paid education and certification programs (clinical and homecare) increase customer lifetime value. Tight SLAs for device uptime command premium pricing, lifting service margins.
- Extended contracts: predictable revenue
- Training: upsell & retention
- SLAs: premium margin
Partnership and value-based deals
ResMed leverages data-driven programs with payers and health systems to share savings, supporting its FY2024 revenue base of about $5.0 billion and enabling outcome-linked contracts that reward patient adherence with shared-risk models that can capture up to ~20% of measurable care-cost reductions.
- Data-sharing: payer/system partnerships
- Outcomes: adherence-linked payments
- Research: collaborative grants and funding
Sleep/respiratory platform drives $5.0B via devices, consumables & SaaS
ResMed's FY2024 revenue base (~$5.0B) is driven by capital equipment sales (CPAPs/ventilators), recurring consumables (masks, cushions, tubing) with short replacement cadences, and growing SaaS/connected-care revenues from monitoring and analytics; bundled services, extended contracts and payer outcome-sharing increase predictability and LTV.
| Stream | FY2024 note |
|---|---|
| Equipment | Core device sales |
| Consumables | High-frequency recurring replacements |
| SaaS/Analytics | Recurring subscriptions, outcome contracts |
| Services | Contracts, training, SLAs |